Cargando…

Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors

BACKGROUND: Programmed cell death receptor ligand 1 (PD-L1) inhibitors are immune checkpoint inhibitors (ICIs) with a side effect profile that may differ from other classes of ICIs such as those directed against cytotoxic T-lymphocyte−associated protein 4 (CTLA-4) and programmed cell death 1 recepto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seethapathy, Harish, Zhao, Sophia, Strohbehn, Ian A., Lee, Meghan, Chute, Donald F., Bates, Halla, Molina, Gabriel E., Zubiri, Leyre, Gupta, Shruti, Motwani, Shveta, Leaf, David E., Sullivan, Ryan J., Rahma, Osama, Blumenthal, Kimberly G., Villani, Alexandra-Chloe, Reynolds, Kerry L., Sise, Meghan E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569697/ https://www.ncbi.nlm.nih.gov/pubmed/33102962 http://dx.doi.org/10.1016/j.ekir.2020.07.011

Ejemplares similares

Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma
por: Seethapathy, Harish, et al.
Publicado: (2020)

Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study
por: Lee, Meghan D, et al.
Publicado: (2021)

Medication-related adverse events in patients with cancer and discrepancies in cystatin C- versus creatinine-based eGFR
por: Hanna, Paul E., et al.
Publicado: (2023)

Effect of Cancer Stage on Adverse Kidney Outcomes in Patients Receiving Immune Checkpoint Inhibitors for Melanoma
por: Wang, Qiyu, et al.
Publicado: (2022)

Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis
por: Qualls, David, et al.
Publicado: (2019)

Medication-Related Adverse Events and Discordancies in Cystatin C–Based vs Serum Creatinine–Based Estimated Glomerular Filtration Rate in Patients With Cancer
por: Hanna, Paul E., et al.
Publicado: (2023)

Acute Kidney Injury Incidence, Recovery, and Long-term Kidney Outcomes Among Hospitalized Patients With COVID-19 and Influenza
por: Strohbehn, Ian A., et al.
Publicado: (2021)

Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study
por: Tiu, Bruce C, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management
por: Seethapathy, Harish, et al.
Publicado: (2021)

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
por: Sise, Meghan E, et al.
Publicado: (2023)

Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
por: Reynolds, Kerry L, et al.
Publicado: (2021)

Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function
por: Seethapathy, Rituvanthikaa, et al.
Publicado: (2023)

Low Complement C4 Predicts Improvement of Kidney Function After Direct‐Acting Antiviral Therapy for Hepatitis C Virus
por: Sise, Meghan E., et al.
Publicado: (2020)

Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
por: Tiu, Bruce C, et al.
Publicado: (2022)

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
por: Hanna, Paul E., et al.
Publicado: (2023)

Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis
por: Durbin, Sienna M, et al.
Publicado: (2020)

COVID-19 Survival and its impact on chronic kidney disease
por: LONG, JOSHUA D., et al.
Publicado: (2022)

Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control
por: Hughes, Michael S., et al.
Publicado: (2019)

Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy
por: Falade, Ayo S., et al.
Publicado: (2022)

Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
por: Zubiri, Leyre, et al.
Publicado: (2021)

Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy
por: Zubiri, Leyre, et al.
Publicado: (2019)

Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021)

Prescription Patterns of Osteoporosis Medications in Patients With Advanced CKD: A Retrospective Cohort Study
por: Portales-Castillo, Ignacio A., et al.
Publicado: (2021)

Acute Kidney Injury Following Paracentesis Among Inpatients With Cirrhosis
por: Seethapathy, Harish, et al.
Publicado: (2020)

Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C–Viremic Donor to Uninfected Recipient Kidney Transplantation
por: Sise, Meghan E., et al.
Publicado: (2020)

Safety and Efficacy of Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir for Hepatitis C Virus Infection Across All Levels of Kidney Function
por: Sise, Meghan E.
Publicado: (2018)

The association between olfactory and gustatory dysfunction and chronic kidney disease
por: Chewcharat, Api, et al.
Publicado: (2022)

Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors
por: Drobni, Zsofia D, et al.
Publicado: (2021)

Therapeutic advances in COVID-19
por: Murakami, Naoka, et al.
Publicado: (2022)

Author Correction: Therapeutic advances in COVID-19
por: Murakami, Naoka, et al.
Publicado: (2023)

Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge
por: Miao, Jing, et al.
Publicado: (2022)

Reply to ‘Use of convalescent plasma in the treatment of COVID-19’
por: Murakami, Naoka, et al.
Publicado: (2023)

Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor–Associated Myocarditis
por: Drobni, Zsofia D., et al.
Publicado: (2020)

Balancing Cancer Immunotherapy Efficacy and Toxicity
por: Johnson, Douglas B., et al.
Publicado: (2020)

Temporal Trends in Inpatient Oncology Census Before and During the COVID‐19 Pandemic and Rates of Nosocomial COVID‐19 Among Patients with Cancer at a Large Academic Center
por: Zubiri, Leyre, et al.
Publicado: (2021)

Methotrexate toxicity treated with continuous venovenous hemofiltration, leucovorin and glucarpidase
por: Connors, Nicholas J., et al.
Publicado: (2014)

Acute kidney injury in patients treated with immune checkpoint inhibitors
por: Gupta, Shruti, et al.
Publicado: (2021)

Remdesivir in Patients With Estimated GFR <30 ml/min per 1.73 m(2) or on Renal Replacement Therapy
por: Estiverne, Christopher, et al.
Publicado: (2020)

Tocilizumab in COVID-19: some clarity amid controversy
por: Gupta, Shruti, et al.
Publicado: (2021)

Risk of COVID‐19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Klebanov, Nikolai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6mh7622i1h7mb1oeq0r6agca99